YMRC
DNLI icon

Yorktown Management & Research Company’s Denali Therapeutics DNLI Stock Holding History

Yorktown Management & Research Company’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$826K Buy
+32,100
New +$660K 0.51% 53

Other funds holding DNLI

EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SOAM
SBI Okasan Asset Management Tokyo, Japan $3.04B AUM
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
BCG
Breakwater Capital Group Paramus, New Jersey $833M AUM 22.71% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Yorktown Management & Research Company's DNLI Position: Q2 2026 in Review

Yorktown Management & Research Company opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 32,100 shares worth $826K. The stake represents 0.51% of the portfolio and ranks #53 among its holdings.

41 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Yorktown Management & Research Company held 32,100 shares of Denali Therapeutics worth $826K as of Q2 2026.
  • Denali Therapeutics was a new Yorktown Management & Research Company position in Q2 2026.
  • Denali Therapeutics made up 0.51% of Yorktown Management & Research Company's portfolio in Q2 2026, its #53 holding.
  • 41 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.